Skip to main content

ARWR Arrowhead Pharmaceuticals, Inc.

Healthcare

59.90 Close 10/30
Since 2024-12-02 +127.4%
Open
59.75
High
61.50
Low
58.74
Prev close
60.49
Volume
1.1M
Amplitude
4.56%
P/B
18.2
Revenue YoY (TTM)
+12.2%
52W 37.06 95.49

Is Arrowhead Pharmaceuticals, Inc. a buy? Fundamentals and valuation first

As of 2026-10-30

Growth: Good, Risk / liquidity: Good; Valuation: Pricey, Quality: Weak.

Valuation Pricey Free-cash-flow yield is Average; Price / book is Expensive.
TTM P/E -26.74 N/A
Price / book 18.18 96th percentile Expensive
Free-cash-flow yield (%) -0.89 41th percentile Average
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Weak FCF margin, TTM is Average; ROE, TTM is Lagging.
ROE, TTM (%) -68.73 14th percentile Lagging
Operating margin, TTM (%) -33.82 20th percentile Average
FCF margin, TTM (%) -11.22 28th percentile Average
Quality Factor Investing: A US Quality Value Backtest
Growth Good Diluted EPS growth, TTM YoY is Top; Revenue growth, TTM YoY is Good.
Revenue growth, TTM YoY (%) 12.22 65th percentile Good
Diluted EPS growth, TTM YoY (%) 72.31 81th percentile Top
Momentum Neutral 240-day return is Top, but 60-day return is Lagging.
60-day return (%) -30.21 17th percentile Lagging
240-day return (%) 45.18 86th percentile Top
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top, but 60-day annualized volatility is Average.
20-day dollar volume 104,403,394 88th percentile Top
60-day annualized volatility (%) 44.7 51th percentile Average
Factor Investing Explained: 10 Classic Factors in US Stocks

Arrowhead Pharmaceuticals, Inc. (ARWR) today

1 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From Arrowhead Pharmaceuticals, Inc. to every stock like it

AI finds several complementary traits of Arrowhead Pharmaceuticals, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. (ARWR) peers and tracking

Watchlist

This page refreshes daily after the close. Add Arrowhead Pharmaceuticals, Inc. to your watchlist to track signal changes on your next visit.

Arrowhead Pharmaceuticals, Inc. (ARWR) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Filed revenue acceleration

Active · now 12.22%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

13 historical occurrences (since 2019-02-07)

Average forward return after Filed revenue acceleration

20-day: Win 61.5%, Sample 13, Median +13.28%, Excess +17.33%, Beat mkt rate 61.5%

60-day: Win 69.2%, Sample 13, Median +19.96%, Excess +21.2%, Beat mkt rate 69.2%

120-day: Win 75%, Sample 12, Median +48.33%, Excess +64.78%, Beat mkt rate 66.7%

120 days after: historical avg +69.02%

20-day +17.72%
60-day +23.57%
120-day +69.02%
20-day
60-day
120-day
Win
61.5%
69.2%
75%
Sample
13
13
12
Median
+13.28%
+19.96%
+48.33%
Excess
+17.33%
+21.2%
+64.78%
Beat mkt rate
61.5%
69.2%
66.7%

Over 12 occurrences, 120-day forward avg gained 69.02%, beat the market by 64.78 pts; win rate 75%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

15 times historically; 60-day forward avg +27.88%, win rate 60%, beating the market by +25.24 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest

16 times historically; 60-day forward avg +24.99%, win rate 73.3%, beating the market by +18.04 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

16 times historically; 60-day forward avg +28.24%, win rate 71.4%, beating the market by +24.04 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.